SARS病毒与其他冠状病毒的基因组比较

本文利用生物信息学方法比较SARS病毒和其他冠状病毒基因组。通过数据库搜索,找出与SARS病毒基因组相似的核酸或蛋白质序列,并对相似序列进行比对,分析它们的共性和差异。结果表明,SARS病毒在基因组的组织上及结构蛋白质方面与现有冠状病毒有比较大的相似性,SARS病毒基因组与冠状病毒基因组相关。但是,SARS病毒基因组还存在一些特异性序列,ORF1a和S蛋白(特别是S1)的变化以及SARS—CoV特异性的非结构蛋白可能是SARS发病机理与传染特性区别于其他冠状病毒的分子基础。在全基因组水平上进行核酸单词出现频率分析,结果表明,SARS病毒远离已知的其他冠状病毒,单独成为一类。     

4株SARS冠状病毒基因组5′端序列的分析与比较

利用5'RACE试剂盒对从中国不同地区、不同SARS患者体中分离的SARS-CoV基因组5'端序列进行RT-PCR扩增,并将扩增产物克隆至T easy vector.扩增片段的序列测定结果表明所分离的4株SARS-CoV基因组5'端非编码区的核苷酸序列和其他国家和地区报道的序列基本一致,而且所形成二级结构也完全相同,但与已知普通冠状病毒的差别较大.同时发现在依赖于RNA的RNA聚合酶起始密码子上游-197 nt处有冠状病毒典型的转录调控核心保守序列5'-CUAAAC-3'.     

4株SARS冠状病毒基因组5’端序列的分析与比较

利用5′RACE试剂盒对从中国不同地区、不同SARS患者体中分离的SARS-CoV基因组5′端序列进行RT-PCR扩增,并将扩增产物克隆至T easy vector。扩增片段的序列测定结果表明:所分离的4株SARS-CoV基因组5′端非编码区的核苷酸序列和其他国家和地区报道的序列基本一致,而且所形成二级结构也完全相同,但与已知普通冠状病毒的差别较大。同时发现在依赖于RNA的RNA聚合酶起始密码子上游-197 nt处有冠状病毒典型的转录调控核心保守序列5′-CUAAAC-3′。     

SARS冠状病毒的分离培养与鉴定

采集急性期病人的咽拭子或漱口液,用Vero 、Vero E6、MDCK、Hela 、Hep-2等传代细胞,人胚肺二倍体细胞(HEL)和人胚肺(HP)细胞分离培养严重急性呼吸系统综合症(SARS)的病原体.结果用Vero、Vero E6、MDCK和HP细胞从标本中分离到一株病毒.间接免疫荧光试验发现,恢复期病人血清可与所分离的病毒起反应,在胞膜和胞浆中出现翠绿色荧光;中和试验结果表明,恢复期病人血清能中和病毒对细胞的致细胞病变作用;电镜下可观察到冠状病毒样颗粒;RT-PCR法可扩增到冠状病毒特异性基因片段,且其核苷酸序列与国内外发表的SARS冠状病毒(SARS-Cov)相应的基因序列相符,同源性达到100%.从传染性非典型肺炎病人的漱口液中分离到SARS冠状病毒,这种病毒与传染性非典型肺炎密切相关.     

SARS病毒与动物冠状病毒的比较

1SARS病毒横空出世 2003年4月16日世界卫生组织宣布,肆虐人类的SARS(Severe Acute Respiratory Syndrome,严重急性呼吸道综合症)即所谓非典型肺炎的病原体已经确定,它是一种全新的寇状病毒,并建议命名为SARS病毒.     

SARS冠状病毒基因结构中未知蛋白Orf7的研究

为探讨SARS-CoV未知蛋白在基因表达调控中的作用,本研究以鉴定的SARS-CoV BJ01毒株cDNA为材料,采用PCR方法扩增SARS-CoV未知蛋白基因Orf7,Orf8,Orf9,引入GFP和pDsRed作为报告基因,构建出5种表达质粒pEGFP-Orf7,pEGFP-Orf8,pEGFP-Orf79,pcDNA3-Orf7,pcDNA3-Orf8.进行体外转染实验后,采用荧光酶标仪测量其细胞中荧光蛋白的表达量,再采用流式细胞仪进一步进行瞬时表达的分析比较.结果发现,pcDNA3-Orf7与pEGFP共转染时,pcDNA3-Orf7能够增强绿色荧光蛋白(GFP)的表达,pEGFP-Orf7与pDsRed共转染时pEGFP-Orf7可以增强红色荧光蛋白(RFP)的表达,且同时表达红色和绿色荧光的细胞数增加.本文首次证明了ORF7编码的63个氨基酸的蛋白具有反式激活作用,即为SARS-CoV自身的反式激活因子.     

SARS病毒与动物冠状病毒的比较

1 SARS病毒横空出世 2003年4月16日世界卫生组织宣布,肆虐人类的SARS(Severe Acute Respiratory Syndrome,严重急性呼吸道综合征)即所谓非典型性肺炎的病原体已经确定,它是一种全新的冠状病毒,并建议命名为SARS病毒。得出这一结论是基于基因序列和动物试验的两个重要依据,其一,包括中国在内     

用SARS冠状病毒全基因组芯片杂交方法分析SARS-CoV

为从临床样品中检测和分析SARSCoV病毒打基础,并为分析SARSCoV病毒的复制和转录等机理提供一种有效方法。以SARS冠状病毒TOR2株序列作为标准设计和制备一种覆盖SARS冠状病毒全基因组的寡聚核苷酸芯片,探针长度为70nt,每相邻的探针序列重复25nt,共660条。用该芯片分析了细胞培养的SARSCoV病毒总RNA、7个SARSCoV病毒的基因克隆片段。对RNA样品用随机引物进行反转录PCR获得cDNA。对DNA用随机引物扩增和dUTPcy3标记。结果用这种芯片杂交检测SARSCoV病毒RNA可见阳性信号呈全基因组分布,并且有多处连续的阳性信号点;用正常人的白细胞RNA为对照,杂交未出现明显阳性信号。检测7个SARSCoV病毒基因克隆片段,在该片段相应的探针区段出现连续阳性信号点。这种方法可有效地检测和分析样品中SARS冠状病毒全基因组的信息。     

SARS病毒核蛋白基因的克隆及其表达研究

从一例输入性传染性非典型性肺炎病人血清中提取病毒RNA,通过RT-PCR方法扩增出SARS病毒核蛋白基因片段,克隆入质粒载体pUCm-T后,进行核苷酸序列的测定及分析,与已公布的SARS病毒基因序列进行比较,证实为SARS冠状病毒核蛋白基因.为了解该病毒核蛋白的抗原特性,将核蛋白基因插入表达载体,构建重组质粒pET28a-SN,转导大肠杆菌BL21(DE3)后,加IPTG诱导表达.产物经SDS-PAGE电泳分析,表达出相对分子量约为50kDa的蛋白,占整个菌体的45%左右.Western-blot分析表明,表达产物仅与SARS阳性病人血清起反应,而与正常血清不起反应.间接ELISA免疫检测,抗原滴度达112500.表明表达的核蛋白为SARS特异性抗原,这为SARS病毒的诊断试剂的研制提供了方便而安全的抗原来源.     

SARS冠状病毒全基因组序列初步分析

对已经完成全序列测定的12个SARS病毒基因组进行了多序列比对,发现序列主体部分29708 b具有99．82％的相同碱基,除2个序列各有5个和6个碱基的缺失外,其余部分共有42个位点核苷酸碱基的差异,其中28个位点的碱基差异可引起氨基酸残基改变。利用蛋白质二级结构和跨膜螺旋预测以及蛋白质定位等生物信息学工具,分析了这些产生氨基酸改变部位的蛋白质构像,推测了可能产生的结构和功能改变,为进一步生物学实验提供参考。所有分析结果同时在北京大学生物信息中心抗SARS网站(antisars.cbi.pku．edu．cn)上发布。     

SARS-Cov及其他冠状病毒基因组比较分析

摘要：对病毒种内和种间基因组的比较分析能获得很多关于病毒起源与演化的信息。对17株SARS-CoV的种内基因组变异分析发现共有137个变异位点,估算出SARS-CoV的突变率为8.04×10-3核苷酸替换/位点/年。变异位点在基因组上的分布不均匀,变异位点最多的是基因组中编码S1蛋白的区域,而在编码依赖于RNA的RNA聚合酶区域中几乎没有变异位点。核苷酸和氨基酸替换的偏性预示变异可能不仅仅是由随机漂变产生。对冠状病毒种间基因组结构比较分析发现,SARS-CoV的基因组结构与IBV很相似;而保守基因系统发育分析表明,SARS-CoV属于冠状病毒的一个新分支,并且与血清型第二组冠状病毒进化关系较近。对其他某些分子特征的分析发现,在不同的方面SARS-CoV和不同组冠状病毒有不同的相似点。进一步对基因组非保守开放阅读框(ORF)的基序(motif)和跨膜区分析发现,各组冠状病毒基因组中位于基因S-E间的非保守ORF可能是同源的,但不是绝对必要的;而IBV和SARS-CoV的基因组中位于基因M-N间ORF可能不是同源的。综合分析SARS-CoV与3组血清型冠状病毒进化关系、宿主分布,以及SARS-CoV和IBV的s2m的进化关系,可以推测SARS-CoV有可能来自禽类。 Abstract:The genome comparison of inter-species and intra-species can give us much information about the origin and evolution of viruses.There are 137 mutation sites in the 17 genomes of SARS-CoV,and the mutation rate is about 8.04×10-3 substitution/site/year.The distribution of the segregating sites is not steady,the most variable region appears in S1 protein,and the nucleotide sequence of RNA-dependent RNA polymerase has very few mutation sites.The substitution bias of nucleotide acids and amino acids indicates the non-random drift products.The comparison of genome structures of SARS-CoV and other coronaviruses shows that SARS-CoV and IBV share the same genome structure.Phylogenetic analyses of conserved genes of coronaviruses indicate that SARS-CoV is a new branch of coronaviruses and appears more close to the group II coronaviruses.Interestingly,SARS-CoV shares some different features with different groups of coronaviruses.Additional analyses show that the first ORFs between S and E genes of some coronaviruses are transmembrane proteins and share the common motif,indicating the possible common ancestor.From the host distribution of different groups of coronaviruses and the phylogeny of s2m,we can deduce that avian is the probable natural host of SARS-CoV.     

猪肠道冠状病毒与入侵受体氨基肽酶N的相互作用

猪肠道冠状病毒是目前危害养猪产业的重要病原。目前已发现能够感染猪肠道的致病性冠状病毒有4种：猪传染性胃肠炎病毒、猪流行性腹泻病毒、猪丁型冠状病毒和猪肠道甲型冠状病毒。冠状病毒感染宿主的第一步是识别宿主细胞膜受体分子并与之结合,随后启动入侵及膜融合进而使病毒基因组进入宿主细胞内部。因此,冠状病毒受体是决定其宿主范围及组织嗜性的关键因素。确定冠状病毒受体及病毒与受体的结合机制对预防新发病毒及开发冠状病毒治疗性药物具有重要意义。猪传染性胃肠炎病毒利用猪氨基肽酶N（aminopeptidase N,APN）作为感染宿主的功能性受体,并利用唾液酸作为辅助结合因子。猪APN最初也被鉴定为猪流行性腹泻病毒的功能性受体,但近年的研究结果与前面的报道存在较大的差异,产生了较大的争议。最近的研究认为,猪丁型冠状病毒的功能性受体也是APN,并且猪丁型冠状病毒能够利用多个物种的APN作为功能性受体,这与其跨物种传播具有密切关系。最新发现的猪肠道甲型冠状病毒则不使用APN作为其入侵受体。本文综述了前面3种猪肠道病毒感染宿主细胞的受体及结合机制的研究进展,并比较分析了猪APN及唾液酸在不同猪肠道冠状病毒入侵宿主过程中结合方式的异同,为进一步研究新发猪肠道冠状病毒受体提供参考。     

冠状病毒研究态势分析

2019年底,一种新型冠状病毒在武汉引起发热性呼吸道疾病(COVID-19),并在我国境内及周边国家持续蔓延,对人类流行病的防控提出了新的要求。基于文献计量学方法梳理了冠状病毒的研究进展,从全球视角对主要研发国家/地区、核心研究机构和热点研究方向进行了分析,旨在揭示冠状病毒的诊断、预防和治疗的研究态势,以期为当前科研联合攻关提供参考。     

Current utilization of interferon alpha for the treatment of coronavirus disease 2019: A comprehensive review

Recent studies have identified an association between perturbed type I interferon (IFN) responses and the severity of coronavirus disease 2019 (COVID-19). IFNα intervention may normalize the dysregulated innate immunity of COVID-19. However, details regarding its utilization and therapeutic evidence have yet to be systematically evaluated. The aim of this comprehensive review was to summarize the current utilization of IFNα for COVID-19 treatment and to explore the evidence on safety and efficacy. A comprehensive review of clinical studies in the literature prior to December 1st_, 2021, was performed to identify the current utilization of IFNα, which included details on the route of administration, the number of patients who received the treatment, the severity at the initiation of treatment, age range, the time from the onset of symptoms to treatment, dose, frequency, and duration as well as safety and efficacy. Encouragingly, no evidence was found against the safety of IFNα treatment for COVID-19. Early intervention, either within five days from the onset of symptoms or at hospital admission, confers better clinical outcomes, whereas late intervention may result in prolonged hospitalization.     

Immune responses and histopathological changes in rabbits immunized with inactivated SARS coronavirus

To evaluate the immunogenicity of inactivated SARS coronavirus (SARS-CoV), three groups of rabbits were immunized three times at 2-week intervals with inactivated vaccine + adjuvant, adjuvant, and normal saline respectively. Eight batchs of serum were sampled from the auricular vein at day 7 to day 51, and specific IgG antibody titers and neutralizing antibody titers were detected by indirect ELISA and micro-cytopathic effect neutralizing test. Antibody specificity was identified by proteinchip assay. Histopathological changes were detected by H&E staining. The results showed that, rabbits in the experimental group immunized with inactivated SARS-CoV all generated specific IgG antibodies with neutralizing activity, which suggested the inactivated SARS-CoV could preserve its antigenicity well and elicit an effective humoral immune responses. The peak titer value of specific IgG antibody and neutralizing antibody reached 1:40960 and 1:2560 respectively. In the experimental group, no obvious histopathological changes was detected in the H&E stained slides of heart, spleen, kidney and testis samples, but the livers had slight histopathological changes, and the lungs presented remarkable histopathological changes. These findings are of importance for SARS-CoV inactivated vaccine development. Foundation item: Joint funds of National Natural Science Foundation of China (U0632010); Program of Guangdong Provincial Key Lab of Bioengineering Medicine (51207026).     

2019新型冠状病毒信息库

2019年12月在中国武汉开始爆发的新型肺炎已造成全球25个国家/地区的31516人感染、638人死亡(截止2020年2月7日16时),引起该肺炎的病毒被世界卫生组织命名为2019新型冠状病毒(2019-nCoV)。为促进2019-nCoV数据共享应用并及时向全球公众提供病毒的相关信息,国家生物信息中心(CNCB)/国家基因组科学数据中心(NGDC)建立了2019新型冠状病毒信息库(2019nCoVR,https://bigd.big.ac.cn/ncov)。该信息库整合了来自德国全球流感病毒数据库、美国国家生物技术信息中心、深圳(国家)基因库、国家微生物科学数据中心及CNCB/NGDC等机构公开发布的2019-nCoV核苷酸和蛋白质序列数据、元信息、学术文献、新闻动态、科普文章等信息,开展了不同冠状病毒株的基因组序列变异分析并提供可视化展示。同时,2019nCoVR无缝对接CNCB/NGDC的相关数据库,提供新测序病毒株系的基因组原始测序数据、组装后序列的在线汇交、管理与共享、国际数据库同步发布等数据服务。本文对2019nCoVR数据汇交、管理、发布及使用等进行全面阐述,以方便用户了解该信息库各项功能及数据状况,为加速开展病毒的分类溯源、变异演化、快速检测、药物研发以及新型肺炎的精准预防与治疗等研究提供重要基础。     

Sequence analysis and structural prediction of the severe acute respiratory syndrome coronavirus nsp5

The non-structural proteins (nsp or replicase proteins) of coronaviruses are relatively conserved and can be effective targets for drugs. Few studies have been conducted into the function of the severe acute respiratory syndrome coronavirus (SARS-CoV) nsp5. In this study, bioinformatics methods were employed to predict the secondary structure and construct 3-D models of the SARS-CoV GD strain nsp5. Sequencing and sequential comparison was performed to analyze the mutation trend of the polymerase nsp5 gene during the epidemic process using a nucleotide-nucleotide basic local alignment search tool (BLASTN) and a protein-protein basic local alignment search tool (BLASTP). The results indicated that the nsp5 gene was steady during the epidemic process and the protein was homologous with other coronavirus nsp5 proteins. The protein encoded by the nsp5 gene was expressed in COS-7 cells and analyzed by sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This study provided the foundation for further exploration of the protein‘s biological function, and contributed to the search for anti-SARS-CoV drugs.     

Molecular cloning, expression, purification, and mass spectrometric characterization of 3C-like protease of SARS coronavirus

Severe acute respiratory syndrome (SARS) is an acute respiratory illness, which has broken out in China. It has been known that SARS coronavirus (SARS_CoV) is a novel human coronavirus and is responsible for SARS infection. Belonging to one of the major proteins associated with SARS_CoV, SARS 3C-like protease (SARS_3CL(pro)) functions as a cysteine protease engaging in the proteolytic cleavage of the viral precursor polyprotein to a series of functional proteins required for coronavirus replication and is considered as an appealing target for designing anti-SARS agents. To facilitate the studies regarding the functions and structures of SARS_3CL(pro), in this report the synthetic genes encoding 3CL(pro) of SARS_CoV were assembled, and the plasmid was constructed using pQE30 as vector and expressed in Escherichia coli M15 cells. The highly yielded ( approximately 15mg/L) expressed protease was purified by use of NTA-Ni(2+) affinity chromatography and FPLC system, and its sequence was determined by LC/MS with the residue coverage of 46.4%.